Navigation Links
Gestiva – the pre-term birth drug probed by FD

According to federal documents released on Monday, a drug that aims to prevent preterm birth doesn’t seem to be effective in delaying the earliest preterm births//, the main cause of death and serious health problems.

Sunnyvale-based Adeza's (NASDAQ:ADZA) drug, Gestiva, is a long-acting form of naturally occurring progesterone and is awaiting federal approval.

The Food and Drug Administration documents reveal that the results of a single clinical trial were not “statistically persuasive” in signifying that Gestiva reduced birth before either 32 or 35 weeks of gestation. But the study proposes that the drug does reduce births before 37th week. Weekly injections of Gestiva results in “substantial reduction” in preterm births among women most at risk, according to Adeza Biomedical Corp. in FDA filings.

According to FDA, even this effect could be “noteworthy”, as several preterm births occur after 32 weeks.

Usually, there are no serious and long-term developmental problems in babies born after 32 weeks of gestation. Whereas, those born before this period though account for only 2% of births, are the majority of cases of death and other problems associated with premature birth.

According to FDA, there is a 29% rise over the last 20 years in premature birth rate in the U.S. that rose to 12% in 2002. Fertility treatments and late pregnancy are the reasons for this rise, the FDA said.

The documents were released by the FDA prior to the meeting on Tuesday where an external panel of experts would recommend whether the drug application filed by the company should be approved by the FDA or not. The drug may cause an increase in miscarriage and stillbirth rate, said the FDA. Will the drug need further research, will be one of the questions posed to the panel. As per FDA rules, the pharmaceutical companies usually, should submit the results of at least 2 clinical trials.

If approved, then Gestiva would be the only FDA-approved drug to avoid preterm birth. This drug is already being manufactured and sold by a few specialty pharmacies without federal approval.

In 1956, the drug was approved by FDA to prevent spontaneous abortion. However, in 2000, the approval was withdrawn by the FDA after its manufacturer stopped selling it.

The drug is proposed to be used in women who already have a history of at least one preterm birth. It is meant to be given as weekly injections from the 16th to 20th week of pregnancy till the 36th week, or birth.
'"/>




Related medicine news :

1. Pregnant mothers dental health can lead to pre-term babies
2. And now live birth on the internet.com?
3. Postpone intercourse after childbirth
4. Relationship bertween birth weight and IQ
5. Link between birth weight and Insulin Resistance
6. Offsprings birth weight affected by fathers diabetes
7. Chance of water births being urged for mums-to-be
8. Boys demand more than girls, even before birth
9. Women who conceive after a year have a higher chance of giving birth prematurely
10. Women who conceive after a year have a higher chance of giving birth prematurely
11. Link between C-section Delivery and Stillbirth
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... ... 2017 , ... "ProDOF is the perfect set of tools for video editors that want to ... said Christina Austin - CEO of Pixel Film Studios. , Video editors using ProDOF ... of a DSLR racking focus from one area into the next. ProDOF comes with ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics (SRO) ... located at 167 Lynch Creek Way. The Petaluma office features three comfortable patient ... and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. ...
(Date:1/20/2017)... Abilene, Texas (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... back the bible in homes across the world. Yisrayl says this generation is a time ... better is to turn to the Bible. , Yisrayl says he does not want to ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... wellness products to enhance people’s everyday lives, recently attended the January ECRM Trade ... , ATP Science is known for its large range of supplements that keep ...
(Date:1/20/2017)... ... ... “Mary Magdalene: Grace is Greater than Sin”: a unique and memorable piece of ... Magdalene: Grace is Greater than Sin” is the creation of published author, Brenda Roberts, ... who had little knowledge of the female characters portrayed in the Holy Bible. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... This report on the opioid induced constipation ... the global market. Large number of chronic pain sufferers ... is a major side effect of consumption of opioid ... therapy has been prescribed to treat opioid induced constipation. ... and growing awareness about the therapy are the major ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA ... drugs market is expected to grow at a CAGR of ... of 38.7% in the second half of the forecast period. The ... 2016 to 2027. The market is estimated at $1,058 million in ... ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017  Abaxis, Inc. ... manufacturing point-of-care blood analysis instruments and consumables for the ... call to discuss its financial results for the third ... call will be at 4:15 p.m. ET on Thursday, ... for the third quarter fiscal year 2017 after the ...
Breaking Medicine Technology: